| scholarly article | Q13442814 |
| P2093 | author name string | Su Young Kim | |
| Eun Ji Choi | |||
| Jeong A Yun | |||
| Eun Sun Jung | |||
| Won Kyung Kang | |||
| Sung Hak Lee | |||
| Jun Gi Kim | |||
| Seung Taek Oh | |||
| P2860 | cites work | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 |
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Genetic alterations during colorectal-tumor development | Q28281200 | ||
| The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. | Q30863657 | ||
| Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer | Q33219573 | ||
| Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors | Q33347864 | ||
| Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma | Q35441324 | ||
| Syndecans: new kids on the signaling block | Q36073431 | ||
| Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP | Q36322742 | ||
| Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas | Q36740664 | ||
| Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase | Q36796844 | ||
| The signaling mechanisms of syndecan heparan sulfate proteoglycans | Q37522781 | ||
| Shedding; towards a new paradigm of syndecan function in cancer | Q37761400 | ||
| Molecular functions of syndecan-1 in disease. | Q37950202 | ||
| Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present). | Q38046230 | ||
| Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab. | Q39283868 | ||
| Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through α2β1 integrin and MT1-MMP. | Q39574618 | ||
| Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma | Q42486776 | ||
| Cancer-associated fibroblasts and epithelial-mesenchymal transition in metastatic oral tongue squamous cell carcinoma | Q43117781 | ||
| Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis | Q43834221 | ||
| High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. | Q44524738 | ||
| Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. | Q44755347 | ||
| Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas | Q46649981 | ||
| Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. | Q50888998 | ||
| Prognostic significance of syndecan-1 expression in squamous cell carcinoma of the tonsil. | Q53334967 | ||
| Syndecan-1 expression in thyroid carcinoma: stromal expression followed by epithelial expression is significantly correlated with dedifferentiation. | Q53377592 | ||
| K-ras gene mutations in adenomas and carcinomas of the colon | Q67510951 | ||
| Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma | Q80587761 | ||
| Syndecan-1 expression in gallbladder cancer and its prognostic significance | Q81434082 | ||
| Prognostic and predictive factors in colorectal cancer | Q85332832 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal carcinoma | Q25493920 |
| P304 | page(s) | 92-99 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | International Journal of Medical Sciences | Q10927439 |
| P1476 | title | Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma: a clinicopathological study of 230 cases | |
| P478 | volume | 12 |
| Q47128720 | Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate |
| Q92286802 | E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy |
| Q47222967 | Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size |
| Q26750872 | Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer |
| Q37702390 | Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma |
| Q27347532 | Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe |
| Q37607965 | KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay |
| Q37406381 | Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer |
| Q48923743 | Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas. |
| Q33820607 | Nuclear Expression of GS28 Protein: A Novel Biomarker that Predicts Prognosis in Colorectal Cancers |
| Q51372167 | Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours. |
| Q36325314 | Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma |
| Q26784262 | Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication |
| Q37686006 | Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways |
| Q91553418 | Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells |
| Q33768220 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. |
Search more.